Skip to main content

Day: September 7, 2021

Genocea to Present at Upcoming Scientific and Investor Conferences

CAMBRIDGE, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) — Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, announced that senior leadership plans to present at the following virtual conferences in September. Scientific conferences:Event: Next Generation Cancer Vaccine Development Summit – DetailsTopic: Neoantigen selection to identify immunogenic tumor specific targets personalized to each patient’s tumor and immune systemFormat: Post Conference WorkshopDate: Thursday, September 9thTime: 1:00 p.m. ETInvestor conferences:Event: H.C. Wainwright 22nd Annual Global Investment Conference (virtual) – DetailsFormat: PresentationDate: Monday, September 13thTime: 7:00 a.m. ETEvent: Baird Global Healthcare Conference 2021 (virtual) –...

Continue reading

Freddie Mac Announces Tender Offer for up to $650 Million Aggregate Original Principal Amount of STACR Debt Notes

MCLEAN, Va., Sept. 07, 2021 (GLOBE NEWSWIRE) — Freddie Mac (OTCQB: FMCC) today announced its fixed-price cash tender offers (each, an “Offer” and, collectively, the “Offers”) for the purchase of the STACR® (Structured Agency Credit Risk) Debt Notes listed below (the “Notes”) beginning Tuesday, Sept. 7, 2021. Freddie Mac has engaged Barclays Capital Inc., the designated lead dealer manager for the Offers, and BofA Securities, Inc. the designated dealer manager for the Offers. Freddie Mac is offering to purchase the Notes listed in the table below, subject to a limit of $650 million in aggregate original principal amount (subject to increase, the “Tender Cap”). The applicable Total Consideration to be paid by Freddie Mac to holders that tender Notes accepted for purchase pursuant to the Offers will be calculated based on the original...

Continue reading

Dada Announces Unaudited Second Quarter 2021 Financial Results

SHANGHAI, China, Sept. 07, 2021 (GLOBE NEWSWIRE) — Dada Nexus Limited (NASDAQ: DADA, “Dada” or the “Company”), China’s leading local on-demand delivery and retail platform, today announced its unaudited financial results for the second quarter ended June 30, 2021. Second Quarter 2021 HighlightsTotal net revenues were RMB1,474.6 million, an increase of 11.5% year over year. Aligning the revenue of Dada Now last-mile delivery services to a comparable basis, revenue growth would have been 81.3% year over year1. Total Gross Merchandise Volume (“GMV”) of JDDJ for the twelve months ended June 30, 2021 was RMB32.3 billion, an increase of 76.7% year over year from RMB18.3 billion in the same period ended June 30, 2020. Number of active consumers for the twelve months ended June 30, 2021 was 51.3 million, as compared with 32.3 million...

Continue reading

Assure Effects Reverse Stock Split and Files Form 8-A in Connection with NASDAQ Listing Application

DENVER, Sept. 07, 2021 (GLOBE NEWSWIRE) — Assure Holdings Corp. (the “Company” or “Assure”) (TSXV: IOM; OTCQB: ARHH), a provider of intraoperative neuromonitoring services (“IONM”), effected a reverse stock split (“Reverse Split”) of its shares of common stock at a ratio of 5 (old) for 1 (new) ratio at 5:30 p.m. (Eastern Time), and filed a Form 8-A with the Securities and Exchange Commission (“SEC”) to register its common stock under Section 12(b) of the Securities Exchange Act of 1934, as amended, for the purpose of qualifying to uplist on the NASDAQ Capital Market (“NASDAQ”). Assure’s common stock will begin trading on the TSX Venture Exchange (TSXV) on a Reverse Split adjusted basis at the open of trading on September 8, 2021, meaning that each five (5) pre-split shares will represent one (1) post-split share and the share price...

Continue reading

PharmaTher Provides Business Highlights and Releases Annual Financials for Fiscal Year Ended May 31, 2021

TORONTO, Sept. 07, 2021 (GLOBE NEWSWIRE) — PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, today released business highlights and financial results for its fiscal year ended May 31, 2021. Unless otherwise indicated, all amounts in this press release are in Canadian dollars.   Fabio Chianelli, Chief Executive Officer of PharmaTher, said, “We had a tremendous year which focused on solidifying exclusive licenses for the development and commercialization of novel ketamine uses and formulations, as well as drug delivery technologies via a microneedle transdermal patch with the aim to change the way how ketamine and psychedelics are used to treat mental health, neurological and pain disorders. In addition, we have strengthened our intellectual property...

Continue reading

TruePillars Live on nCino in 12 Weeks Following Joint Deployment with KPMG

New Australian SME Lender completes accelerated delivery of nCino’s cloud-based platform MELBOURNE, Australia and WILMINGTON, N.C., Sept. 07, 2021 (GLOBE NEWSWIRE) — nCino, Inc. (NASDAQ: NCNO), a pioneer in cloud banking and digital transformation solutions for the global financial services industry, today announced that TruePillars, a specialist SME lending company headquartered in Melbourne, Australia, is live on the nCino Bank Operating System®. TruePillars selected KPMG Australia as their delivery partner, who in conjunction with the nCino team in Australia, were able to transform the TruePillars’ lending process rapidly and get their users live on the nCino platform in only 12 weeks. “As a start-up in the Australian financial services ecosystem, we knew we needed partners who could get us up and running quickly, who were flexible...

Continue reading

ECN Capital Announces Its Intention to Renew its Normal Course Issuer Bid for Common Shares and Preferred Shares

TORONTO, Sept. 07, 2021 (GLOBE NEWSWIRE) — ECN Capital Corp. (“ECN Capital” or the “Company”) today announced that it has filed notices of intention with the Toronto Stock Exchange (the “TSX”) to renew its normal course issuer bid (the “Common Share Bid”) for its common shares (“Common Shares”) and a normal course issuer bid (the “Preferred Share Bid” and, together with the Common Share Bid, the “Bids”) for the Company’s Series A 6.50% Rate Reset Preferred Shares (“Series A Preferred Shares”) and Series C 6.25% Rate Reset Preferred Shares (“Series C Preferred Shares” and, together with the Series A Preferred Shares, “Preferred Shares”). If these notices are accepted by the TSX, the Bids would permit the Company to repurchase for cancellation, at its discretion during the 12 months following such acceptance, up to 10% of the “public...

Continue reading

Fairfax India Receives All Regulatory Approvals to Complete Sale of Minority Position of Anchorage Infrastructure

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES (Note: All dollar amounts in this news release are expressed in U.S. dollars, except as otherwise noted). TORONTO, Sept. 07, 2021 (GLOBE NEWSWIRE) — Fairfax India Holdings Corporation (“Fairfax India” or the “Company”) (TSX: FIH.U) announces that it has received all regulatory approvals required to complete the previously announced transaction to sell approximately 11.5% (on a fully-diluted basis) of its interest in Anchorage Infrastructure Investments Holdings Limited (“Anchorage”) for gross proceeds of approximately INR 9.5 billion (approximately $129 million at current exchange rates). The Company intends to close the transaction as soon as practicable. Anchorage is a subsidiary of Fairfax India and will be its flagship company for investing...

Continue reading

Voxtur Analytics Announces Grant of Stock Options and Engagement of IR Service Provider

TORONTO and TAMPA, Fla., Sept. 07, 2021 (GLOBE NEWSWIRE) — Voxtur Analytics Corp. (TSXV: VXTR; OTCQB: VXTRF) (“Voxtur” or the “Company”), a technology company creating a more transparent and accessible real estate lending ecosystem, announced today that, in accordance with the Company’s Stock Option Plan approved at the Annual and Special Meeting of Shareholders on June 10, 2021, and the Director Compensation Plan as outlined in the Company’s Management Information Circular dated May 5, 2021, the Company granted a total of 1,750,000 stock options to non-management Directors. These options have an exercise price of $0.80 and will expire five years from the grant date if not exercised. Vesting of these stock options will be 25% per calendar quarter, in arrears. A complete copy of the Company’s...

Continue reading

Ocugen, Inc. to Present at Upcoming Citi and H.C. Wainwright Investment Conferences

MALVERN, Pa., Sept. 07, 2021 (GLOBE NEWSWIRE) — Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to fight COVID-19, today announced that it will be participating in Citi’s 16th Annual BioPharma Virtual Conference being held on September 8-10, 2021 and at the H.C. Wainwright Global Investment Conference being held on September 13-15, 2021. Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder will present virtually at Citi’s conference and Sanjay Subramanian, CFO and Head of Corporate Development will present virtually at H.C. Wainwright. Both will provide updates on COVAXIN™, the investigational COVID-19 vaccine which the company is co-developing with Bharat Biotech for the U.S. and Canadian markets....

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.